Skip to main content
OpenTrials
Completed

NCT Number: NCT03449628

L. Casei DG® in Patients With Irritable Bowel Syndrome.

To assess the effect of L. casei DG® (Lactobacillus paracasei CNCMI1572; Enterolactis® plus) on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients with IBS (Irritable Bowel Syndrome). Patients will be randomized to receive L. casei DG® capsules, b.i.d. for 12 weeks the a 4 weeks Follow Up period will follow.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

A.O. Bolognini, Seriate, BG, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years and ≤ 65 years
  • A positive diagnosis of non constipated IBS (i.e., IBS-D and IBS-M, both males and females), according to Rome IV criteria.
  • A negative outcome of colonoscopy performed within 5 years before screening if patient is at least 50 years old, or if patient meet any of the following alarm features:
  • Has a documented weight loss within the past 6 months; or
  • Has nocturnal symptoms; or
  • Has a familiar history of colon cancer; or
  • Has blood mixed with their stool (excluding blood from hemorroids).
  • Negative relevant additional screening or consultation whenever appropriate
  • Ability to conform to the study protocol.

Exclusion criteria

  • Patients with IBS-C or IBS-U according to Rome IV criteria
  • Presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant on the basis of predefined values, (i.e..liver or kidney functional levels 2-times greater than the upper reference values)
  • Ascertained intestinal organic diseases, including celiac disease, food allergies or inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular disease, infectious colitis, ischemic colitis, microscopic colitis).
  • Previous major abdominal surgery.
  • Active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment are also acceptable).
  • Untreated food intolerance such as ascertained or suspected lactose intolerance, as defined by anamnestic evaluation or, if appropriate, lactose breath test.
  • Use of probiotics or topical and/or systemic antibiotic therapy during the last month.
  • Systematic/frequent use of contact laxatives.
  • Pregnant females or females of childbearing potential in the absence of effective contraceptive methods.
  • Inability to conform to protocol.
  • Treatment with any investigational drug within the previous 30 days.
  • Recent history or suspicion of alcohol abuse or drug addiction.
  • Presence of red or white flags at the Rome IV Psychosocial Alarm Questionnaire for Functional gastrointestinal Disorders.

Treatment and study plan

L.casei DG

Dietary Supplement

(At least 24 billion live cells per capsule)

1 capsule, b.i.d. for 12 weeks

Placebo

Dietary Supplement

1 capsule, b.i.d. for 12 weeks

Primary outcomes

  1. Proportion of patients who have a response in pain

    Time frame: 12 weeks

    Patients who record on ≥ 50% of the days a reduction of ≥ 30% from their average baseline score for their worst abdominal pain.The standard 11-point numeric rating scale (from 0=none to 10=worst possible pain) will be used to measure abdominal pain.

  2. Proportion of patients who have a response in stool consistencies

    Time frame: 12 weeks

    Patients who record a stool-consistency score < 5 in the same days in which they record a reduction of ≥ 30% from their average baseline score for their worst abdominal pain .For abnormal defecation, stool frequency and form will be measured using the Bristol Stool Form Scale (BSFS).

Secondary outcomes

  1. Evaluation of Pain relief

    Time frame: 16 weeks

    reduction of ≥ 30% from baseline in the score for the worst abdominal pain on ≥ 50% of days

  2. Evaluation of global symptom score

    Time frame: 16 weeks

    Improvement in the global symptom score: a score of 0 or 1, or an improvement ≥ 2 over the baseline score, on ≥ 50% of days

  3. Relief of IBS symptoms

    Time frame: 16 weeks

    Adequate relief of IBS symptoms on ≥ 50% of the past weeks (a response of "yes" on ≥50% of the weeks to the following question: "Over the past week, have you had adequate relief of your IBS symptoms?)"

  4. IBS-SSS score questionnaire (Severity Scoring System )

    Time frame: 16 weeks

    To assess the severity of symptoms related to Irritable Bowel Syndrome, assessed at baseline and at the end of treatment after 12 weeks (it is considered clinically significant a score reduction of at least 50 points). The questionnaire is composed by five questions wich generate a maximum score of 100 each using prompted visual analogue scales, leading to a total possible score of 500.

  5. Improvement in stool consistency

    Time frame: 16 weeks

    stool consistency score ≤ 5 assessed with BSFS (Bristol Stool Form Scale) BSFS evaluates stool form and consistency (score from 1=dry stool to 7=liquid stoo. The ideal stool is generally 3 or 4)

  6. Satisfaction with treatment

    Time frame: 16 weeks

    Overall satisfaction with treatment assessed by VAS scale (Visual Analogue Scale)

  7. Quality of life

    Time frame: 16 weeks

    Quality of life assessment by validated Short-Form 12 Items Health Survey (SF-12) on a scale of 0 to 100

  8. Intake of rescue medication

    Time frame: 16 weeks

    type and frequencies of rescue medication

  9. gut microbiota composition

    Time frame: 16 weeks

    Evaluation of changes in the gut microbiota composition and the relative abundance of bacterial OTUs (Operational Taxonomic Unit).

  10. Short Chain Fatty Acids (SCFA)

    Time frame: 16 weeks

    Evaluation of Short Chain Fatty Acids levels in fecal samples

  11. Free Aminoacids

    Time frame: 16 weeks

    Evaluation of Free aminoacids levels in fecal samples

  12. Biogenic Amines

    Time frame: 16 weeks

    Evaluation of biogenic amines levels in fecal samples

  13. Gut permeability for zonulin

    Time frame: 16 weeks

    evaluation of serum levels of zonulin

  14. Gut permeability for citrulline

    Time frame: 16 weeks

    evaluation of serum levels of citrulline

  15. Gut permeability for PV-1 (Plasmalemma vesicle-associated) protein

    Time frame: 16 weeks

    evaluation of serum levels of PV-1 (Plasmalemma vesicle-associated) protein

  16. L. casei DG® strain in the feces

    Time frame: 16 weeks

    the recovery of L. casei DG® strain in the feces

Sponsors and collaborators

Lead sponsor

SOFAR S.p.A.

Industry

Collaborators

  • 1Med

Registry information

Official study title

L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.

Acronym: PROBE2

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Feb 28, 2018
Registry last updated
May 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.